I2O Therapeutics, Inc.
Records under this name other than the patents I2O Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 11 patents it holds.
Back to I2O Therapeutics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| 17/121,576 | Implant Placement and Removal Systems Abandoned Abandoned May 9, 2024 | Abandoned | Abandoned May 9, 2024 | |
| 17/996,126 | Long Acting Glucagon Receptor Selective Peptides and Methods of Use Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 17/996,131 | Use of Human Amylin Analog Polypeptides for Providing Superior Glycemic Control to Type 1 Diabetics Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/176,094 | Ionic Liquid Formulations for Treating Diabetes Abandoned Abandoned May 27, 2026 | Abandoned | Abandoned May 27, 2026 | |
| 18/319,010 | Methods Comprising Continuous Administration of a GLP-1 Receptor Agonist and Co-administration of a Drug Abandoned Abandoned Jul 27, 2025 | Abandoned | Abandoned Jul 27, 2025 | |
| 18/490,341 | Glucagon-Receptor Selective Polypeptides and Methods of Use Thereof Abandoned Abandoned Feb 16, 2026 | Abandoned | Abandoned Feb 16, 2026 | |
| 18/501,735 | Ionic Liquid Formulations for Treating Inflammatory and Autoimmune Diseases Abandoned Abandoned Nov 9, 2026 | Abandoned | Abandoned Nov 9, 2026 | |
| 18/598,763 | Implant Placement and Removal Systems Abandoned Abandoned Mar 21, 2025 | Abandoned | Abandoned Mar 21, 2025 | |
| 18/779,857 | Long Acting Glucagon Like POLYPEPTIDE-1 (GLP-1) Receptor Agonists and Methods of Use Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/889,043 | Long Acting Peptide Tyrosine Tyrosine (PYY) Analogs and Methods of Use Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. |